KLRS Kalaris Therapeutics Inc
USHealthcareAs of 2026-08-24
Why KLRS matters now
Kalaris Therapeutics Inc (KLRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.10 with -1.20% on the session and $89.5M in market capitalization; recent performance reads 1-month +0.43% and YTD -44.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.9M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -55.6%.
The latest indexable market news headline is "Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes PATTERSON LEONE D filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.63
P/S
0.00
EV/EBITDA
-1.25
DCF Value
$6.25
FCF Yield
-55.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.8%
ROA
-40.2%
ROIC
-46.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.9M | $-0.46 |
| Q4 2025 | $0.00 | $-10.0M | $-0.44 |
| FY 2025 | $0.00 | $-43.4M | $-2.85 |
| Q3 2025 | $0.00 | $-11.9M | $-0.64 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$18.25
Target (Median)
$18.00
Target Range
$14.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.14
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.